due to a reduced financial guidance for 2023, driven by higher interest rates. The new revenue guidance is between $500 million and $510 million, compared to previous estimates of $530 million to $540 million. In the third quarter, the company expects EPS of $0.59 to $0.60.
@BloombergT actually a madness for a profitable company. The new increased targets were simply too optimistic for this new market environment with high interest rates. But the company is virtually debt-free and continues to make a profit.$INMD remains on my buy list.
